Documents show how Cerebral used social media ads to grow its ADHD drug business, as federal prosecutors look into possible Controlled Substance Act violations
The online mental health company surged to a $4.8 billion valuation after it started dispensing ADHD medication …
Context & Ripple Effects
Cerebral's arc runs from a $1.23 billion app-based mental health raise in mid-2021 to a $4.8 billion valuation after it began dispensing ADHD medication — growth that reporting has already tied to looser pandemic prescribing rules and pressure on clinicians, including 30-minute online evaluations. The new documents add a marketing layer: paid social media acquisition funnels feeding that prescription volume.
The prosecutorial angle is not hypothetical. Federal authorities have already arrested and charged the founder and head doctor of rival telehealth firm Done Global over an alleged Adderall prescription scheme, and separate reporting documented telehealth companies running social media ads promoting drugs for unapproved uses without risk disclosures. Cerebral is now the second major player in this cohort facing Controlled Substances Act scrutiny.
First-order effects
- Federal prosecutors are examining whether Cerebral's ad-driven ADHD prescribing violated the Controlled Substances Act, putting the company's core growth engine — and the clinicians who prescribed under its funnel — under direct legal exposure.
- Investors who marked Cerebral up from $1.23 billion to $4.8 billion on the strength of medication-dispensing revenue now hold a stake whose value depends on the outcome of a federal investigation.
Second-order effects
- Done Global's prosecution shows where this path leads: if Cerebral follows, every telehealth startup that scaled stimulant prescribing through online evaluations faces forced retrenchment — tighter clinician oversight, slower intake, and higher compliance costs that compress the unit economics behind those valuations.
- Ad platforms and paid-testimonial channels used by these companies come under scrutiny as distribution infrastructure for controlled-substance marketing, raising acquisition costs across the telehealth category.
Third-order effects
- If the pattern holds — pandemic-era flexibility converted into enforcement cases against the fastest-growing prescribers — the telehealth ADHD market structurally consolidates around operators who can absorb compliance overhead, while regulators formalize limits on remote controlled-substance prescribing and direct-to-consumer drug advertising.
- The broader lesson for digital health is that valuations built on regulatory arbitrage carry embedded legal liabilities that surface years later, reshaping how later-stage capital prices prescribing-dependent models.
The trend: Telehealth prescribing startups that scaled on loosened pandemic rules are being progressively converted into enforcement targets, with Cerebral's ad-fueled ADHD business the latest and largest case.